3,4-Di-tert-butylfuran | 22808-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 3,4-Di-tert-butylfuran
• 英文别名: 3,4-di-t-butylfuran；3,4-Ditert-butylfuran
• CAS: 22808-05-5
• 化学式: C₁₂H₂₀O
• 分子量: 180.29
• InChiKey: BYSIBNVWRRMCRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3,4-di-t-butylthiophene 1,1-dioxide 400.0 ℃ 、26.66 Pa 条件下， 以12%的产率得到3,4-Di-tert-butylfuran
  参考文献：
  名称：

  Synthesis and characterization of 3,4-dl-t-butylfuran, pyrrole, and selenophene

  摘要：

  DOI：

  10.1016/s0040-4039(00)97652-4

文献信息

• SUBSTITUTED SULFONAMIDE COMPOUNDS
  申请人：OBERBOERSCH Stefan

  公开号：US20080153843A1

  公开（公告）日：2008-06-26

  Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

  磺胺取代物，其制备方法，含有这些化合物的药物组合物，以及磺胺取代物在治疗或抑制疼痛和/或各种疾病或疾病状态中的用途。
• HEPATITIS B ANTIVIRAL AGENTS
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20160289212A1

  公开（公告）日：2016-10-06

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： X-A-Y-Z-L-R 1 （I） 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• AZAINDOLE INHIBITORS OF AURORA KINASES
  申请人：DHANAK Dashyant

  公开号：US20070149561A1

  公开（公告）日：2007-06-28

  The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

  本发明涉及一种由化学式（I）表示的化合物： 及其药学上可接受的盐。本发明的化合物抑制极化激酶，使其特别适用于治疗多种疾病，包括实体肿瘤癌和血液系统癌症。
• CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME
  申请人：Nakamura Masaharu

  公开号：US20110152523A1

  公开（公告）日：2011-06-23

  The present invention provides a process for efficiently producing an alkylated aromatic compound in good yield, by a cross-coupling reaction between an alkyl halide and an aromatic magnesium reagent. A process for producing an aromatic compound represented by Formula (1): R—Ar′  (1) wherein R is a hydrocarbon group, and Ar′ is an aryl group; the process comprising: reacting a compound represented by Formula (2): R—X  (2) wherein X is a halogen atom, and R is as defined above, with a magnesium reagent represented by Formula (3): Ar′—MgY  (3) wherein Y is a halogen atom, and Ar′ is as defined above, in the presence of a catalyst for cross-coupling reactions comprising an iron compound and a bisphosphine compound represented by Formula (4): wherein Q is a divalent group derived from an aromatic ring by removing two hydrogen (H) atoms on adjacent carbon atoms; and each Ar is independently an aryl group.

  本发明提供了一种高效产生烷基芳香化合物的方法，通过烷基卤化物和芳香镁试剂之间的交叉偶联反应，以良好的产率产生烷基芳香化合物的方法，所述方法包括：将由式（2）表示的化合物：R—X（2）其中X是卤素原子，R如上所定义，与由式（3）表示的镁试剂：Ar′—MgY（3）其中Y是卤素原子，Ar′如上所定义，在交叉偶联反应的催化剂存在下反应，所述催化剂包括一种铁化合物和一种由式（4）表示的双膦化合物：其中Q是通过去除相邻碳原子上的两个氢（H）原子从芳香环中衍生的二价基团；每个Ar都是独立的芳基团。
• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。